Article
A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models.
Toxicological sciences : an official journal of the Society of Toxicology - 1 Dec 2012
Harrill Alison H, Desmet Kristina D, Wolf Kristina K, Bridges Arlene S, Eaddy J Scott, Kurtz C Lisa, Hall J Ed, Paine Mary F, Tidwell Richard R, Watkins Paul B
Abstract excerpt
DB289 is the first oral drug shown in clinical trials to have efficacy in treating African trypanosomiasis (African sleeping sickness). Mild liver toxicity was noted but was not treatment limiting. However, development of DB289 was terminated when several treated subjects developed severe kidney injury, a liability not predicted from preclinical testing. We tested the hypothesis that the kidney safety liability...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.